KR20090119897A - 점막의 질환으로 인한 조직 악화, 상처 또는 손상을 치료 또는 예방하는 방법 - Google Patents

점막의 질환으로 인한 조직 악화, 상처 또는 손상을 치료 또는 예방하는 방법 Download PDF

Info

Publication number
KR20090119897A
KR20090119897A KR1020097018913A KR20097018913A KR20090119897A KR 20090119897 A KR20090119897 A KR 20090119897A KR 1020097018913 A KR1020097018913 A KR 1020097018913A KR 20097018913 A KR20097018913 A KR 20097018913A KR 20090119897 A KR20090119897 A KR 20090119897A
Authority
KR
South Korea
Prior art keywords
days
mucositis
scv
day
radiation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020097018913A
Other languages
English (en)
Korean (ko)
Inventor
이스라엘 리오스
신시아 투실
Original Assignee
사이클론 파아머슈티컬 인코오퍼레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 사이클론 파아머슈티컬 인코오퍼레이티드 filed Critical 사이클론 파아머슈티컬 인코오퍼레이티드
Publication of KR20090119897A publication Critical patent/KR20090119897A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020097018913A 2007-02-13 2008-02-11 점막의 질환으로 인한 조직 악화, 상처 또는 손상을 치료 또는 예방하는 방법 Withdrawn KR20090119897A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90097707P 2007-02-13 2007-02-13
US60/900,977 2007-02-13

Publications (1)

Publication Number Publication Date
KR20090119897A true KR20090119897A (ko) 2009-11-20

Family

ID=39690681

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020097018913A Withdrawn KR20090119897A (ko) 2007-02-13 2008-02-11 점막의 질환으로 인한 조직 악화, 상처 또는 손상을 치료 또는 예방하는 방법

Country Status (14)

Country Link
US (2) US7906486B2 (enExample)
EP (1) EP2120986A4 (enExample)
JP (1) JP2010518160A (enExample)
KR (1) KR20090119897A (enExample)
CN (1) CN101657210A (enExample)
AR (1) AR065338A1 (enExample)
AU (1) AU2008216799A1 (enExample)
CA (1) CA2677749A1 (enExample)
IL (1) IL200364A0 (enExample)
MX (1) MX2009008641A (enExample)
NZ (1) NZ579570A (enExample)
TW (1) TW200845958A (enExample)
UA (1) UA96980C2 (enExample)
WO (1) WO2008100458A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2677749A1 (en) * 2007-02-13 2008-08-21 Sciclone Pharmaceuticals, Inc. Method of treating or preventing tissue deterioration, injury or damage due to disease of mucosa
RU2436587C1 (ru) * 2010-10-21 2011-12-20 Общество с ограниченной ответственностью "ЦитоНИР" (ООО "ЦитоНИР") N-изовалероил-l-глутамил-l-триптофан как средство, препятствующее язвообразованию в желудке и двенадцатиперстной кишке
CN109528202B (zh) * 2018-11-14 2021-07-16 北京大学第一医院 一种头颈部放疗诊疗系统

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4125626A (en) * 1977-01-17 1978-11-14 Mt. Sinai School Of Medicine Of The City University Of New York Synthesis and use of L-γ-glutamyl-DOPA
US4568489A (en) * 1984-06-29 1986-02-04 E. R. Squibb & Sons, Inc. N-Acyl-γ-glutamyl imino and amino acids and esters
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4758551A (en) * 1986-07-08 1988-07-19 Cornell Research Foundation, Inc. Methods for combatting renal toxicity due to metals or nephrotoxic drugs and for selectively modulating in vivo formation of leukotriene types
US4968672A (en) * 1987-01-02 1990-11-06 The United States Of America As Represented By The Department Of Health And Human Services Adenosine receptor prodrugs
US4895835A (en) * 1987-11-20 1990-01-23 Nisshin Oil Mills, Ltd. Muramyl peptide derivatives and use thereof
US5728680A (en) * 1987-12-30 1998-03-17 Cytoven J.V. Methods for normalizing numbers of lymphocytes
US5902790A (en) * 1995-10-03 1999-05-11 Cytran, Inc. Pharmaceutical angiostatic dipeptide compositions and method of use thereof
US5206220A (en) * 1990-04-23 1993-04-27 Research Corporation Technologies, Inc. Soluble and stable sources of tyrosine, cysteine and glutamine for total parenteral nutrition
WO1992017191A1 (en) 1991-04-01 1992-10-15 Cytoven Pharmaceutical dipeptide compositions and methods of use thereof
WO1993008815A1 (en) 1991-10-28 1993-05-13 Cytoven Pharmaceutical dipeptide compositions and methods of use thereof
WO1994020063A2 (en) 1993-03-04 1994-09-15 Cytoven International N.V. Pharmaceutical tryptophan containing dipeptide compositions and methods of use thereof
GB9320820D0 (en) * 1993-10-08 1993-12-01 Biokine Tech Ltd Compounds for medicinal use
RU2107692C1 (ru) * 1995-06-07 1998-03-27 Дейгин Владислав Исакович Пептид и способ его получения
US5888980A (en) * 1994-06-30 1999-03-30 Bio-Logic Research And Development Corporation Compositions for enhancing immune function
US5916878A (en) * 1995-11-28 1999-06-29 Edward T. Wei γ-glutamyl and β-aspartyl containing immunomodulator compounds and methods therewith
US5744452A (en) * 1995-11-28 1998-04-28 Edward T. Wei γ-L-glutamyl containing immunomodulator compounds and methods therewith
RU2120298C1 (ru) 1995-11-28 1998-10-20 Товарищество с ограниченной ответственностью "Верта" Иммуностимулятор и препарат на его основе
WO1997019691A1 (en) 1995-11-28 1997-06-05 Wei, Edward, T. Gamma-l-glutamyl containing immunomodulator compounds and methods therewith
US6060452A (en) * 1996-03-13 2000-05-09 Cytran, Inc. Analogs of L-Glu-L-Trp having pharmacological activity
RU2141483C1 (ru) 1997-07-04 1999-11-20 Небольсин Владимир Евгеньевич Производные пептидов или их фармацевтически приемлемые соли, способ их получения, применение и фармацевтическая композиция
US7173013B2 (en) * 2001-06-08 2007-02-06 Sciclone Pharmaceuticals, Inc. Treatment of tuberculosis using immunomodulator compounds
RU2229892C2 (ru) 2001-06-08 2004-06-10 Государственное учреждение "Санкт-Петербургский научно-исследовательский институт фтизиопульмонологии" Способ лечения туберкулеза легких
US20050256042A1 (en) * 2003-05-09 2005-11-17 Jeffers Michael E Methods of preventing and treating alimentary mucositis
AU2005244826B2 (en) * 2004-05-14 2010-07-29 Sciclone Pharmaceuticals, Inc. Treatment or prevention of respiratory viral infections with immunomodulator compounds
JP4874985B2 (ja) 2004-10-27 2012-02-15 サイクローン・ファーマシューティカルズ・インコーポレイテッド 免疫調節化合物による出血性ウイルス感染の治療又は予防
WO2006076169A2 (en) 2004-12-28 2006-07-20 Sciclone Pharmaceuticals, Inc. Treatment or prevention of genital viral infections with immunomodulator compounds
US20090074815A1 (en) * 2005-04-22 2009-03-19 Sciclone Pharmaceuticals, Inc. Immunomodulator Compounds as Vaccine Enhancers
AU2007240946A1 (en) * 2006-04-20 2007-11-01 Sciclone Pharmaceuticals, Inc. Treatment of melanoma
JP2010513508A (ja) 2006-12-18 2010-04-30 アキリオン ファーマシューティカルズ，インコーポレーテッド Ｃ型肝炎感染を処置するための併用療法
CA2677749A1 (en) * 2007-02-13 2008-08-21 Sciclone Pharmaceuticals, Inc. Method of treating or preventing tissue deterioration, injury or damage due to disease of mucosa
RU2007118237A (ru) 2007-05-17 2008-11-27 ООО "Научно-производственна фирма Верта" (RU) Способ лечения аллергических заболеваний
US20110189305A1 (en) 2007-08-23 2011-08-04 Tuthill Cynthia W Treatment of lung cancer
JP2011530519A (ja) 2008-08-06 2011-12-22 サイクローン・ファーマシューティカルズ・インコーポレイテッド 免疫調節化合物を用いたｃ型肝炎の治療または予防の方法

Also Published As

Publication number Publication date
NZ579570A (en) 2012-02-24
EP2120986A4 (en) 2010-04-07
CA2677749A1 (en) 2008-08-21
US20100086622A1 (en) 2010-04-08
WO2008100458A2 (en) 2008-08-21
AU2008216799A1 (en) 2008-08-21
MX2009008641A (es) 2009-09-14
EP2120986A2 (en) 2009-11-25
UA96980C2 (ru) 2011-12-26
IL200364A0 (en) 2010-04-29
TW200845958A (en) 2008-12-01
CN101657210A (zh) 2010-02-24
JP2010518160A (ja) 2010-05-27
US7906486B2 (en) 2011-03-15
AR065338A1 (es) 2009-06-03
WO2008100458A3 (en) 2008-11-27
US20110117211A1 (en) 2011-05-19

Similar Documents

Publication Publication Date Title
ES2235499T3 (es) Uso de derivados de propionil l-carnitina y de acetil l-carnitina en la preparacion de medicamentos con actividad anticancerigena.
Epstein et al. Oral Kaposi's sarcoma in acquired immunodeficiency syndrome. Review of management and report of the efficacy of intralesional vinblastine
JPH05505170A (ja) 成長因子による口内粘膜炎の治療および予防
EP2185581B1 (en) Methods and compositions useful in the treatment of mucositis
JP2000514415A (ja) ソマトスタチン類似体およびラパマイシンの配合
KR20180100309A (ko) 데옥시콜산 및 이의 염을 사용한 축적된 지방의 치료 방법
WO2014017046A1 (ja) 放射線障害の予防及び／又は治療剤
CN116726021B (zh) 一种drp1抑制剂和铁死亡诱导剂联合用药物及其抗肿瘤的用途
KR20090119897A (ko) 점막의 질환으로 인한 조직 악화, 상처 또는 손상을 치료 또는 예방하는 방법
ES2351665T3 (es) Derivados de benzamidina para el tratamiento y la prevención de mucositis.
US5964224A (en) Method for treating amyotrophic lateral sclerosis and a therapeutic agent therefor
TW200410683A (en) Medicament for preventing and/or treating peripheral neuropathies
US8163702B2 (en) Treatment of melanoma
WO2017173308A1 (en) Radiation mitigator and method of use thereof
RU2721282C2 (ru) Способ лечения рассеянного склероза (варианты)
KR20050086819A (ko) 알파 티모신을 사용한 방사능 손상에 대한 보호방법
JP3022915B2 (ja) 癌転移抑制剤
KR20210039414A (ko) 암의 치료를 위한 병용 요법
US7846901B2 (en) Method for inhibiting or treating intestinal damage caused by radiotherapy or chemotherapy comprising administering substance-P
ES2316977T3 (es) Uso de un antagonista de adrenorreceptor alfa2 para el tratamiento de la epilepsia.
TW202515897A (zh) 溶瘤肽及其用途
CN108853483B (zh) 经修饰的胸腺素β4在治疗脑缺血再灌注损伤方面的用途
KR100674604B1 (ko) 싸이클릭다이펩타이드를 주성분으로 하는 방사선 보호제
CN119343360A (zh) 溶瘤肽及其用途
CN111407748A (zh) 酪醇在制备治疗脑胶质瘤的药物中的应用

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20090910

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid